Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Reports Positive Phase 1 Results for GLPG1205

Published: Wednesday, December 04, 2013
Last Updated: Wednesday, December 04, 2013
Bookmark and Share
Company is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

Galapagos NV has announced that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

The aim of the Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205. The randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium.

In the first part of the study, single ascending doses were evaluated. In the second part, the new compound was administered daily for 14 days.

GLPG1205 was safe and well-tolerated over a wide dose range in healthy volunteers. Engagement of the thus far undisclosed novel target was confirmed using a relevant biomarker.

GLPG1205 displayed a favorable pharmacokinetic and pharmacodynamic profile, potentially supporting once-daily dosing. The data shown in Phase 1 encourage Galapagos to progress GLPG1205 into a Phase 2A study in Inflammatory Bowel Disease (IBD).

"GLPG1205 is the first molecule against this target ever to be evaluated clinically, and we are pleased with the outcome of the Phase 1 study," said Piet Wigerinck, CSO of Galapagos. "Galapagos continues to deliver novel therapeutics from its unique target and drug discovery engine. GLPG1205 will be the fourth compound to enter Phase 2A in our portfolio of proprietary and partnered programs based on novel targets."

In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs.

These programs include a novel target for inflammatory disorders that was identified and validated by Galapagos using its proprietary target discovery engine.

Subsequent Galapagos research led to the discovery of GLPG1205, a first-in-class molecule that entered the clinic for inflammatory disorders. Galapagos is responsible for execution of Phase 1 and Phase 2A studies with GLPG1205.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Tuesday, August 25, 2015
Patient Recruitment Completed in FITZROY Phase 2 Crohn's Disease Study
First selective JAK1 inhibitor in Phase 2 in Crohn's disease.
Friday, August 07, 2015
Galapagos Completes Recruitment for ORIGIN Phase 2 Trial
Recruitment for the Phase 2 Proof-of-Concept study with GPR84 inhibitor GLPG1205 in ulcerative colitis patients.
Saturday, June 20, 2015
Galapagos DARWIN 1 and 2 Studies have Completed 24 Weeks of Treatment
Topline results from final analyses expected to be released in July and August 2015.
Thursday, June 11, 2015
Galapagos Regains Rights to GLPG1690
Filing for Phase 2 clinical trial in 2015.
Thursday, March 19, 2015
Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program
Research will focus on compounds against viral protein targets and on inhibitors of host cell proteins.
Thursday, February 12, 2015
Galapagos Receives €2.5 Million IWT Grant for Antibiotic Research
Grant to support the development of Galapagos’ novel antibiotics in a collaboration project.
Saturday, January 24, 2015
Galapagos Completes Recruitment for Darwin 2 Monotherapy Study
Study will begin a series of topline readouts starting around end of the first quarter 2015.
Monday, November 24, 2014
Galapagos Presents Favorable Phase 1 Data for IBD Target
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.
Tuesday, October 21, 2014
Bart Filius Joins Galapagos as CFO
Bart will join the Executive Committee of Galapagos and be responsible for Finance, Investor Relations, IT, and Purchasing.
Saturday, October 18, 2014
Galapagos Receives Milestone in Osteoarthritis Alliance with Servier
Company completes the nomination of new pre-clinical candidate in the alliance with Servier.
Thursday, August 07, 2014
Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier
Company is responsible for discovery and development of new candidate drugs.
Tuesday, March 11, 2014
Galapagos Receives €2.3 Million IWT Grant for Fibrosis Research
Aim of IWT grant is to deliver a comprehensive fibrosis research platform.
Tuesday, February 04, 2014
Galapagos Receives €2.9 Million IWT Grant for Cystic Fibrosis Research
Project to identify and progress multiple promising CF therapies towards pre-clinical candidates.
Monday, January 13, 2014
Galapagos Selects Pre-Clinical Candidate for Cystic Fibrosis
Start of Phase 1 expected before end 2014.
Tuesday, December 17, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!